141,068 AbbVie Inc. $ABBV Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 4.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,706,187 shares of the company’s stock after acquiring an additional 141,068 shares during the quarter. AbbVie accounts for about 1.1% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 14th biggest holding. Robeco Institutional Asset Management B.V. owned 0.21% of AbbVie worth $969,501,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. State Street Corp lifted its holdings in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP acquired a new stake in AbbVie in the 2nd quarter worth about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in AbbVie during the 2nd quarter worth approximately $2,905,952,000. Finally, Deutsche Bank AG increased its stake in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $288.66 on Wednesday. The stock has a market capitalization of $510.01 billion, a P/E ratio of 81.54, a PEG ratio of 1.29 and a beta of 0.24. The company has a 50 day moving average price of $264.22 and a 200 day moving average price of $240.39. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin ?4?7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466
• Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise
• Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals
• Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren
• Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market

Analysts Set New Price Targets

Several research analysts recently commented on ABBV shares. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 price objective on shares of AbbVie in a research note on Tuesday, October 13th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Oppenheimer raised their price target on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.